Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Rocket Pharmaceuticals (RCKT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.58 | $65.00 | $39.00 | 128.87% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Rocket Pharmaceuticals comes to $50.58. The forecasts range from a low of $39.00 to a high of $65.00. The average price target represents an increase of 128.87% from the last closing price of $22.10.
Analyst Price Targets (12)
Broker Rating
Rocket Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.21 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.08 a month ago based on 13 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 7.14% of all recommendations. A month ago, Strong Buy made up 92.31%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.21 | 1.21 | 1.08 | 1.08 | 1.08 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
2/13/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
1/31/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
12/26/2023 | LifeSci Capital | Cory Jubinville | Not Available | Strong Buy |
12/1/2023 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
8/11/2023 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.21 |
ABR (Last week) | 1.21 |
# of Recs in ABR | 14 |
Average Target Price | $50.58 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.69 |